Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

A NON-INVASIVE, ADAPTIVE DIGITAL THERAPEUTIC SOLUTION FOR POST-TRAUMATIC STRESS DISORDER AND OTHER MENTAL DISORDERS

Project description

Innovative digital therapeutics for post-traumatic stress disorder

Post-traumatic stress disorder (PTSD) is a mental health condition that can develop after experiencing or witnessing a traumatic event. Characterised by symptoms such as flashbacks, nightmares, avoidance and hyperarousal, PTSD is especially hard to treat. The EU-funded GrayMatters for PTSD - GfP project proposes a non-invasive digital therapeutics device. It uses advanced statistical models, EEG and fMRI to develop a biomarker associated with the amygdala and emotion regulation system to enhance patients' self-control over this brain activity level, which is associated with fear and anxiety. The solution has shown positive results in initial clinical trials on stress resilience in PTSD patients. The project has the potential to make a significant impact on the lives of PTSD patients worldwide.

Objective

Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at €7.5B. Current treatments’ success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasive
digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.

Coordinator

GRAYMATTERS HEALTH LTD
Net EU contribution
€ 2 500 000,00
Address
HAATZMAUT ST 82
3303403 Haifa
Israel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 594 250,00